Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index; 22 of the 198 sources its claims cite were checked for support.

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease

Open access
Khan, Sahil, Barve, Kalyani H., Kumar, Maushmi S. · 2020 · Current Neuropharmacology

Abstract

BACKGROUND: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other form of dementia. However, due to the non-feasibility of such methods, to diagnose and conclude the conditions, medical practitioners use tests that examine a patient's mental ability. OBJECTIVE: Accurate diagnosis at an early stage is the need of the hour for initiation of therapy. The cause for most Alzheimer's cases still remains unknown except where genetic distinctions have been observed. Thus, a standard drug regimen ensues in every Alzheimer's patient, irrespective of the cause, which may not always be beneficial in halting or reversing the disease progression. To provide a better life to such patients by suppressing existing symptoms, early diagnosis, curative therapy, site-specific delivery of drugs, and application of hyphenated methods like artificial intelligence need to be brought into the main field of Alzheimer's therapeutics. METHODS: In this review, we have compiled existing hypotheses to explain the cause of the disease, and highlighted gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics and quantum dots as advancements in the existing strategies to manage Alzheimer's. CONCLUSION: Biomarkers, brain-imaging, and theranostics, along with artificial intelligence, are understood to be the future of the management of Alzheimer's.

Overview

CoChat Summary

TL;DR

This narrative review summarizes proposed mechanisms of Alzheimer’s disease (AD), current diagnostic approaches, and emerging therapeutic strategies including gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics, theranostics/quantum dots, and artificial intelligence. It argues that early diagnosis and multimodal, mechanism-targeted approaches are needed because existing treatments only relieve symptoms and no available drug halts or reverses disease progression.

Key findings

  • AD pathogenesis is described through multiple hypotheses: Aβ plaque formation, tau hyperphosphorylation and neurofibrillary tangles, synaptic dysfunction and neurotransmitter imbalance, neuroinflammation, infectious disease, gut microbiome disruption, genetic mutations, oxidative stress, and autophagy dysfunction. The review notes that amyloid-targeting drugs have shown no effect in reversing or halting cognitive decline, suggesting either the hypothesis is incorrect or the brain becomes refractory after a certain time.
  • For diagnosis, the paper reports that specialized PET scanning exhibits 100% specificity and 96% sensitivity in AD and milder conditions, while CSF analysis for p-tau, Aβ42, and total tau has 85–90% accuracy. It also states that pathological changes are initiated two decades before symptoms appear, and that P-tau181 can serve as a confirmatory and prognostic biomarker.
  • Currently approved drugs target cholinergic or glutamatergic neurotransmission: donepezil, rivastigmine, and galantamine are acetylcholinesterase inhibitors effective in mild to moderate AD; memantine, approved by the FDA in 2003, is an NMDA receptor antagonist for moderate to severe AD. These drugs only relieve symptoms, and no drug is available with a curative effect.
  • Emerging strategies include gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics/prebiotics/exercise, theranostics with quantum dots, and AI-based diagnosis. Examples include deep learning with 18F-FDG PET achieving 82% specificity and 100% sensitivity at an average of 75.8 months ahead of final diagnosis, and voice/speech machine-learning classifiers reporting accuracies from 74% to 94.71%.

Methods

  • Design: narrative review compiling existing hypotheses and highlighting gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics, and quantum dots as advancements in AD management.
  • Data/sample: no primary data collection; the paper synthesizes prior literature, including human trials, animal models, and biomarker studies.
  • Main analysis: qualitative synthesis of mechanisms, diagnostics, current FDA-approved medicines, and future therapeutic/diagnostic approaches, including artificial intelligence.

Limitations

  • Stated in the paper: various hypotheses are unable to explain the complete picture of AD pathogenesis; the cause in many cases remains untraceable; no treatment options can halt or reverse disease progression; gene therapy and quantum dots are recent additions but are yet to be clinically approved; most immunotherapeutics are in Phase 3 clinical trials; peptidomimetics, speech as an indicator, and metal ion chelators are still under investigation and not widely used.
  • Evident from the text: this is a narrative review without a described systematic search strategy, formal inclusion/exclusion criteria, or meta-analysis; it relies on cited studies that include animal models, small cohorts, and preliminary human data, and it does not perform a formal risk-of-bias or quality assessment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2174/1570159x18666200528142429

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. (1) Mechanisms involved in pathogenesis of Alzheimer’s disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (1) Mechanisms involved in pathogenesis of Alzheimer’s disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central
Fig. (2) Current strategies in treatment and newer strategies in early detection and treatment of Alzheimer’s disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).
Fig. (2) Current strategies in treatment and newer strategies in early detection and treatment of Alzheimer’s disease. (A higher resolution / colour version of this figure is available in the electronic copy of the article).CC BY-NC · PubMed Central

Verification

Claims the paper makes

20 Valid · 2 Not valid · 159 Not checked · 11 Own results and interpretations

89 more claims · 5 with their cited sources checked

Create a free account to see all 192 claims and to verify the 176 references still open.

See all claims — free account
  • It may state two separate claims as one. 90
  • Probably not a substantial claim. 12
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 136 references

Research works printed but not linked: 7

  1. Grimm M.O.W.; Hartmann T.; Recent understanding of the molecular mechanisms of Alzheimer’s disease. J Addict Res Ther 2012(S5), 004
  2. Fillit H.M.; We need new biomarkers for Alzheimer’s Disease
  3. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines World Health Organization
  4. Wong C.B.; Kobayashi Y.; Xiao J-Z.; Neuroscience 2018,85-104
  5. Al-Hameed S.; Benaissa M.; Christensen H.; Simple and robust audio-based detection of biomarkers for Alzheimer’s disease proceeding of the 7th workshop on speech and language processing for Assistive Technologies (SLPAT), San Francisco, USA, 201, pp. 32-36.
  6. De Brito Sanchez R.; de Barros L.; Rodrigues S.C.M.; Fernandes J.C.L.; Bondioli A.C.V.; de Campos Mundin H.A.; de Sousa V.D.S.; da Silva L.H.B.O.; Artificial Intelligence to Detect Alzheimer’s in Magnetic Resonances, IFMBE Proceedings of the XXVI Brazilian Congress on Biomedical Engineering; Costa-Felix, R.; Machado, J.; Alvarenga, A. (eds), Singapore, Int Psychogeriatr 2019,7(2),59-63
  7. Farooq A.; Anwar S.M.; Awais M.; Alnowami M.; Proceedings of the IEEE International Smart Cities Conference 2017,1-4

Cited by

See all 820

Metadata

Authors
Khan, S., Barve, K. H., & Kumar, M. S.
Affiliations
Narsee Monjee Institute of Management Studies (IN)
Corresponding author
Kumar, Maushmi S.
Venue
Current Neuropharmacology
Published
2020-11-09
Volume
18
Issue
11
Pages
1106-1125
ISSN
1570-159X (ISSN-L)
OpenAlex
W3030743313
Cited by
820
References
136
Citations by year
2026: 106 · 2025: 242 · 2024: 234 · 2023: 193 · 2022: 38 · 2021: 4 · 2020: 3
FWCI
7.59
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Current Neuropharmacology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, pathogenesis, early diagnosis, biomarkers, neuroimaging, theranostics, gene therapy, immunotherapy, peptidomimetics, metal chelators, probiotics, quantum dots, artificial intelligence, drug delivery
MeSH terms
Alzheimer Disease, Animals, Brain, Humans, Biomarkers, Disease Progression, Early Diagnosis, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. https://app.cochat.ai/papers/10.2174/1570159x18666200528142429
The paper
Khan, S., Barve, K. H., & Kumar, M. S. (2020). Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Current Neuropharmacology. https://doi.org/10.2174/1570159x18666200528142429

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.